<table id="t15" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 15. Summary of Drug Interactions With Lamotrigine</caption>
<col align="left" valign="top" width="34%"></col>
<col align="center" valign="top" width="33%"></col>
<col align="center" valign="top" width="33%"></col>
<thead>
<tr valign="middle">
<th stylecode="Lrule Rrule">Drug</th>
<th stylecode="Rrule">Drug Plasma Concentration With Adjunctive Lamotrigine<footnote>From adjunctive clinical trials and volunteer studies.</footnote>
</th>
<th stylecode="Rrule">Lamotrigine Plasma Concentration With Adjunctive Drugs<footnote>Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteers studies.</footnote>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↔ = No significant effect.</td>
</tr>
<tr>
<td align="left" colspan="3">? = Conflicting data.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Lrule Rrule">Oral contraceptives (e.g., ethinylestradiol/levonorgestrel)<footnote>The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.</footnote>
</td>
<td stylecode="Rrule">↔<footnote>Modest decrease in levonorgestrel.</footnote>
</td>
<td stylecode="Rrule">↓</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Bupropion </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Carbamazepine (CBZ) </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↓</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">CBZ epoxide<footnote>Not administered, but an active metabolite of carbamazepine.</footnote>
</td>
<td stylecode="Rrule">?</td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Felbamate </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Gabapentin </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Levetiracetam </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Lithium </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">Not assessed</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Olanzapine </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↔<footnote>Slight decrease, not expected to be clinically relevant.</footnote>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Oxcarbazepine </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr valign="bottom">
<td stylecode="Lrule Rrule">10-monohydroxy oxcarbazepine metabolite<footnote>Not administered, but an active metabolite of oxcarbazepine.</footnote>
</td>
<td stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Phenobarbital/primidone </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↓</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Phenytoin (PHT) </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↓</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Pregabalin </td>
<td stylecode="Rrule">↔ </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Rifampin </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↓</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Topiramate </td>
<td stylecode="Rrule">↔<footnote>Slight increase, not expected to be clinically relevant.</footnote>
</td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Valproate </td>
<td stylecode="Rrule">↓ </td>
<td stylecode="Rrule">↑</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Valproate + PHT and/or CBZ </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↔</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Zonisamide </td>
<td stylecode="Rrule">Not assessed </td>
<td stylecode="Rrule">↔</td>
</tr>
</tbody>
</table>